Protea Biosciences, Inc. is a new Biotechnology company, based in Morgantown, West Virginia, that has been founded to advance and commercialize new Proteomics technology, under development at the West Virginia University Health Sciences Center (WVU). The Company was incorporated in July, 2001
The Founders of the company include a team of leading researchers at the West Virginia University Health Sciences Center, and Stephen Turner, General Partner of Origins LLC. Protea’s Scientific Advisors are as follows:
|John Barnett, PhD. – |
Professor and Chairman of the Department of Microbiology, Immunology and Cell Biology, WVU. Dr. Barnett has an extensive background in the fields of immunology and immune responsiveness (signal transduction cascades).
|Barbara Ducatman, M.D. – |
Professor and Chairman of the Department of Pathology, WVU School of Medicine.
|Daniel Flynn, PhD. – ||Associate Professor of Microbiology, Immunology and Cell Biology, and Associate Director for Basic Research, the Mary Babb Randolph Cancer Center, WVUHSC. Dr. Flynn is responsible for the cell signaling research program.|
|Aaron Timperman, PhD. – ||Assistant Professor of Chemisty. Dr. Timperman came to WVU from the University of Washington Department of Molecular Biotechnology, and|
specializes in the development and application of microfluidics technology to Proteomics.
|William Wardell, M.D., Ph.D. – |
Formerly Senior Vice President, Drug Development, Parke-Davis,
and a Merck International Fellow in Clinical Pharmacology.
In Partnership with the WVU Core Proteomics Laboratory, the company is undertaking the discovery of novel cellular proteins to identify new targets for drug and assay development. Initially, the primary disease focus is Cancer; however, the company anticipates that proteomic opportunities in many therapeutic areas will be identified.